BACKGROUND: Radiation dermatitis developing in patients receiving cetuximab concomitantly with radiotherapy for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) is now recognized to have different pathophysiological and clinical characteristics to the radiation dermatitis associated with radiotherapy or concomitant chemotherapy and radiotherapy. Current grading tools were not designed to grade this type of radiation dermatitis; their use may lead to misclassification of reactions and inappropriate management strategies, potentially compromising cancer treatment. PATIENTS AND METHODS: An advisory board of seven leading European specialists (three medical oncologists, three radiation oncologists and a dermatologist) with extensive experience of the use of cetuximab plus radiotherapy produced consensus guidelines for the grading and management of radiation dermatitis in patients receiving cetuximab plus radiotherapy. RESULTS: Modifications to the current, commonly used National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.3 for grading radiation dermatitis were proposed. Updated management guidelines, building on previously published guidelines from 2008, were also proposed. CONCLUSIONS: The proposed revisions to the grading system and updated management guidelines described here represent important developments toward the more appropriate grading and effective management of radiation dermatitis in patients receiving cetuximab plus radiotherapy for LA SCCHN.
BACKGROUND:Radiation dermatitis developing in patients receiving cetuximab concomitantly with radiotherapy for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) is now recognized to have different pathophysiological and clinical characteristics to the radiation dermatitis associated with radiotherapy or concomitant chemotherapy and radiotherapy. Current grading tools were not designed to grade this type of radiation dermatitis; their use may lead to misclassification of reactions and inappropriate management strategies, potentially compromising cancer treatment. PATIENTS AND METHODS: An advisory board of seven leading European specialists (three medical oncologists, three radiation oncologists and a dermatologist) with extensive experience of the use of cetuximab plus radiotherapy produced consensus guidelines for the grading and management of radiation dermatitis in patients receiving cetuximab plus radiotherapy. RESULTS: Modifications to the current, commonly used National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.3 for grading radiation dermatitis were proposed. Updated management guidelines, building on previously published guidelines from 2008, were also proposed. CONCLUSIONS: The proposed revisions to the grading system and updated management guidelines described here represent important developments toward the more appropriate grading and effective management of radiation dermatitis in patients receiving cetuximab plus radiotherapy for LA SCCHN.
Authors: Peter Arne Gerber; Stephan Meller; Tatiana Eames; Bettina Alexandra Buhren; Holger Schrumpf; Sonja Hetzer; Laura Maximiliane Ehmann; Wilfried Budach; Edwin Bölke; Christiane Matuschek; Andreas Wollenberg; Bernhard Homey Journal: Eur J Med Res Date: 2012-02-23 Impact factor: 2.175
Authors: Elvio G Russi; Marco C Merlano; Gianmauro Numico; Renzo Corvò; Marco Benasso; Riccardo Vigna-Taglianti; Antonella Melano; Nerina Denaro; Stefano Pergolizzi; Ida Colantonio; Francesco Lucio; Rodolfo Brizio; Umberto Ricardi Journal: Support Care Cancer Date: 2011-11-13 Impact factor: 3.603
Authors: Andrea L DiCarlo; Aaron C Bandremer; Brynn A Hollingsworth; Suhail Kasim; Adebayo Laniyonu; Nushin F Todd; Sue-Jane Wang; Ellen R Wertheimer; Carmen I Rios Journal: Radiat Res Date: 2020-09-16 Impact factor: 2.841
Authors: Samuel Finkelstein; Lauren Kanee; Tara Behroozian; Julie Ryan Wolf; Corina van den Hurk; Edward Chow; Pierluigi Bonomo Journal: Support Care Cancer Date: 2022-01-24 Impact factor: 3.603